Drug Database
DO

donepezil hydrochloride (Aricept jelly / donepezil jelly)

✓ Approved

Eisai Co., Ltd. · ACHE · Small Molecule

What is donepezil hydrochloride?

donepezil hydrochloride is a small molecule developed by Eisai Co., Ltd.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesAricept jelly, donepezil jelly
CompanyEisai Co., Ltd.
Drug ClassSmall Molecule
Molecular TargetACHE
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

donepezil hydrochloride acts on 1 molecular target:

ACHEacetylcholinesterase (Cartwright blood group) (N-ACHE, ACEE)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

donepezil hydrochloride is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Nervous system disordersDementia Alzheimer's type✓ Approved
Nervous system disordersDementia with Lewy bodies✓ Approved

Related Research Articles

PubMedInflammopharmacology2026-10-15

Synergistic approaches to Alzheimer's disease: exploring the combined efficacy of phytoconstituents and conventional drugs.

Kumar Abhishek A

Cognitive functions deteriorate with Alzheimer's disease (AD), a kind of degenerative disease. Problems with memory, interpersonal interactions, problem-solving, and other cognitive functions that limit a person's ability to do daily tasks are the hallmarks of dementia. This condition affects about 50 million individuals globally. Traditional therapies for AD, like galantamine, donepezil, and memantine, only offer symptomatic alleviation through glutamatergic regulation and cholinergic augmentation, making AD a significant worldwide health concern. This review assesses the possibility of improving the effectiveness of therapy by combining significant phytoconstituents with traditional AD therapies. A complete literature review was carried out using peer-reviewed publications, experimental investigations, and review papers published from 2010 to 2025. The primary objective of the investigation was to study the interaction between phytoconstituents and conventional therapy in the treatment of Alzheimer's disease. Our outcomes demonstrate the powerful multi-target adjuvant properties of curcumin, resveratrol, quercetin, berberine, and luteolin. In particular, Berberine and Quercetin considerably reduce neuroinflammation and oxidative stress through the Nrf2/HO-1 and NF-κB pathways, whereas Curcumin and resveratrol enhance the anti-amyloidogenic effects of conventional medications. Additionally, luteolin exhibits a special capacity to regulate tau hyperphosphorylation, which enhances memantine's stabilising neurotransmitter actions. The primary objective of therapy has shifted from symptomatic relief to disease modification by the synergy between phytoconstituent and conventional drugs. These combinations preserve the structural integrity of the cholinergic synapse by concurrently mitigating oxidative stress and amyloid toxicity. A possible paradigm shift towards holistic neuroprotection is represented by the incorporation of these five essential phytoconstituents into traditional AD regimens. To ensure clinical translatability, future research must now focus on nanoformulations that can overcome the limited bioavailability of substances like curcumin. These methods may improve treatment effectiveness, lessen adverse effects, and reduce the chance of resistance, providing a more thorough method of handling the complexities of AD.

PubMedNature2026-10-14

A mysterious jelly seems to be left behind by toads.

PubMedCurrent drug safety2026-10-14

Bilateral Lower Extremity Edema During Donepezil Treatment: A Case Report.

Kang Kyusik K

Introduction/ Background: Acute bilateral lower-extremity edema is uncommon and often results from medication side effects, acute heart failure, nephrotic syndrome, or bilateral deep vein thrombosis. Drugs such as dihydropyridine calcium channel blockers, corticosteroids, thiazolidinediones, and nonsteroidal anti-inflammatory agents are known to cause edema. Donepezil, a widely used acetylcholinesterase inhibitor for Alzheimer's disease, has not been previously linked to leg edema. Recognizing rare adverse reactions is essential for patient safety, as edema may indicate serious conditions. Case Presentation: A 75-year-old woman with Alzheimer's disease developed bilateral pitting lower leg edema six months after starting treatment with donepezil. She had no history of cardiac, renal, hepatic, or venous diseases. Laboratory tests, electrocardiography, chest X-ray, and computed tomography venogram were normal, except for mild anemia and a slightly reduced estimated glomerular filtration rate. The edema resolved three weeks after discontinuation and did not recur after the administration of rivastigmine. Conclusion: The temporal association and resolution upon drug cessation suggest a probable association. Possible mechanisms may include cholinergic-induced vasodilation, which increases capillary permeability.

PubMedBMC pharmacology & toxicology2026-10-14

Correction to: In vitro comparative quality evaluation of different brands of metformin hydrochloride tablets available in Mekelle City, Tigray Regional State, Ethiopia.

Welegebrial Brhane Gebrehiwot BG, Gezae Zenawi Z, Gebrekidan Samrawit Kidanemariam SK, Gebrerufael Gebru Gebremeskel GG et al.

PubMedBiochemistry and biophysics reports2026-10-14

Hybrid spheroids of urine-derived renal epithelial cells: Structural and functional characterization.

Pizzuti Valeria V, Balducelli Emma E, Bin Sofia S, Demetri Marcello M et al.

Urine-derived Renal Epithelial Cells (URECs) are voided in urine after acute kidney damage and in response to ischemia reperfusion events. We previously investigated the phenotype and immunomodulatory properties of URECs derived from kidney transplanted patients. Here, we establish a 3D model combining URECs with Wharton's Jelly Mesenchymal Stromal Cells (WJ-MSCs), to evaluate structure, cell distribution and viability of the spheroids. Immunomodulatory properties were analysed by coculturing spheroids with Peripheral Blood Mononuclear Cells (PBMCs); CD4+ and CD8+ T cells proliferation, and the percentage of regulatory T cells (Treg) and Granzyme B+ cells were evaluated. Spheroids were obtained combining URECs and WJ-MSCs, with URECs located in the core of the aggregate and WJ-MSCs in the outer layer. In a PBMC co-culture system, hybrid spheroids reduced CD4+ and CD8+ T cells proliferation, and the Granzyme B+ cells percentage, while increasing Tregs. Our data demonstrate the stability and immunomodulatory capacity of URECs:WJ-MSCs spheroids, providing a basis to investigate immunomodulatory pathways and unexplored effects of this novel 3D cell model.

PubMedDrug metabolism and bioanalysis2026-10-14

Revisiting Cinacalcet HCl Hepatic Disposition: Insights from Isolated Perfused Rat Liver.

Mireskandari Katayoon K, Barazesh Ahmadreza A, Rostamnezhad Mostafa M, Darabi Majid M et al.

Hepatic drug handling determines systemic exposure, yet the balance between tissue uptake, intracellular binding, and metabolic clearance is difficult to dissect in vivo. Cinacalcet hydrochloride (CINA), a calcimimetic used to manage secondary hyperparathyroidism, has low oral bioavailability and is widely described as a high-extraction drug subject to extensive hepatic metabolism. Whether tissue sequestration rather than biotransformation underlies its rapid hepatic removal has not been tested directly in an intact ex vivo liver model. We investigated the hepatic clearance of cinacalcet hydrochloride (CINA) using the isolated perfused rat liver (IPRL) model. A validated high-performance liquid chromatography (HPLC) method was established to quantify CINA and its primary metabolite, M7, in both liver tissue and perfusate samples. To evaluate the influence of perfusate composition and protein binding, experiments were conducted under single-pass perfusion modes, in the presence and absence of bovine serum albumin (BSA). Dose recovery and mass balance analysis indicated that ~93% of the administered dose was recovered: ~63% in liver tissue and ~29% in the outlet perfusate. No metabolites were detected in any sample, pointing to tissue uptake and retention as the dominant clearance mechanism. Drug loss to plastic perfusion tubing was substantial and was only partially offset by BSA. Inclusion of BSA also shifted the apparent drug distribution between liver and perfusate. In the IPRL, hepatic tissue sequestration rather than metabolic conversion was the dominant clearance mechanism for CINA. Non-specific adsorption to plastic perfusion tubing and the protein content of the perfusion medium were important confounders that must be controlled in future ex vivo studies. CINA was extensively retained in rat liver tissue with negligible in situ metabolism over 90 min of single-pass perfusion, raising the question of whether metabolic extraction truly explains its low oral bioavailability in vivo.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about donepezil hydrochloride